These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. Babulal GM; Ghoshal N; Head D; Vernon EK; Holtzman DM; Benzinger TLS; Fagan AM; Morris JC; Roe CM Am J Geriatr Psychiatry; 2016 Nov; 24(11):1095-1104. PubMed ID: 27426238 [TBL] [Abstract][Full Text] [Related]
4. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets. Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL; Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677 [TBL] [Abstract][Full Text] [Related]
6. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study. Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM; J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495 [TBL] [Abstract][Full Text] [Related]
7. Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Ben Bouallègue F; Mariano-Goulart D; Payoux P; Alzheimers Res Ther; 2017 Apr; 9(1):32. PubMed ID: 28441967 [TBL] [Abstract][Full Text] [Related]
8. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
9. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028 [TBL] [Abstract][Full Text] [Related]
10. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study. Xiong C; Jasielec MS; Weng H; Fagan AM; Benzinger TL; Head D; Hassenstab J; Grant E; Sutphen CL; Buckles V; Moulder KL; Morris JC Neurology; 2016 Apr; 86(16):1499-506. PubMed ID: 27009258 [TBL] [Abstract][Full Text] [Related]
12. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378 [TBL] [Abstract][Full Text] [Related]
13. Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort. Wang ML; Wei XE; Yu MM; Li PY; Li WB; Neurosci Lett; 2017 Aug; 655():115-120. PubMed ID: 28689050 [TBL] [Abstract][Full Text] [Related]
14. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
15. Predicting Driving Cessation Among Cognitively Normal Older Drivers: The Role of Alzheimer Disease Biomarkers and Clinical Assessments. Babulal GM; Chen L; Murphy SA; Carr DB; Morris JC Neurology; 2024 Jun; 102(12):e209426. PubMed ID: 38776513 [TBL] [Abstract][Full Text] [Related]
16. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653 [TBL] [Abstract][Full Text] [Related]
17. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR; Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824 [TBL] [Abstract][Full Text] [Related]